MRI for Cushing Disease: A Systematic Review

References

1. 1.↵
   1. Castle-Kirszbaum M,
   2. Wang YY,
   3. King J, et al

   . Quality of life following endoscopic surgical management of pituitary adenomas. Neurosurgery 2022;90:81–91 doi:10.1227/NEU.0000000000001740 pmid:34982874

   CrossRefPubMed
2. 2.↵
   1. Ntali G,
   2. Asimakopoulou A,
   3. Siamatras T, et al

   . Mortality in Cushing’s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 2013;169:715–23 doi:10.1530/EJE-13-0569 pmid:23996696

   Abstract/FREE Full Text
3. 3.↵
   1. Chowdhury IN,
   2. Sinaii N,
   3. Oldfield EH, et al

   . A change in pituitary magnetic resonance imaging protocol detects ACTH-secreting tumours in patients with previously negative results. Clin Endocrinol (Oxf) 2010;72:502–06 doi:10.1111/j.1365-2265.2009.03646.x pmid:19500112

   CrossRefPubMed
4. 4.↵
   1. Batista D,
   2. Courkoutsakis NA,
   3. Oldfield EH, et al

   . Detection of adrenocorticotropin-secreting pituitary adenomas by magnetic resonance imaging in children and adolescents with Cushing disease. J Clin Endocrinol Metab 2005;90:5134–40 doi:10.1210/jc.2004-1778 pmid:15941871

   CrossRefPubMed
5. 5.↵
   1. Patronas N,
   2. Bulakbasi N,
   3. Stratakis CA, et al

   . Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. J Clin Endocrinol Metab 2003;88:1565–69 doi:10.1210/jc.2002-021438 pmid:12679440

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Jagannathan J,
   2. Smith R,
   3. DeVroom HL, et al

   . Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease: clinical article. J Neurosurg 2009;111:531–39 doi:10.3171/2008.8.JNS08339 pmid:19267526

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Lonser RR,
   2. Wind JJ,
   3. Nieman LK, et al

   . Outcome of surgical treatment of 200 children with Cushing’s disease. J Clin Endocrinol Metab 2013;98:892–901 doi:10.1210/jc.2012-3604 pmid:23372173

   CrossRefPubMed
8. 8.↵
   1. Cristante J,
   2. Lefournier V,
   3. Sturm N, et al

   . Why we should still treat by neurosurgery patients with Cushing disease and a normal or inconclusive pituitary MRI. J Clin Endocrinol Metab 2019 May 14 [Epub ahead of print] doi:10.1210/jc.2019-00333 pmid:31087046

   CrossRefPubMed
9. 9.↵
   1. Dai C,
   2. Feng M,
   3. Sun B, et al

   . Surgical outcome of transsphenoidal surgery in Cushing’s disease: a case series of 1106 patients from a single center over 30 years. Endocrine 2022;75:219–27 doi:10.1007/s12020-021-02848-1 pmid:34415482

   CrossRefPubMed
10. 10.↵
    1. Lonser RR,
    2. Nieman L,
    3. Oldfield EH

    . Cushing’s disease: pathobiology, diagnosis, and management. J Neurosurg 2017;126:404–17 doi:10.3171/2016.1.JNS152119 pmid:27104844

    CrossRefPubMed
11. 11.↵
    1. Wind JJ,
    2. Lonser RR,
    3. Nieman LK, et al

    . The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing’s disease. J Clin Endocrinol Metab 2013;98:2285–93 doi:10.1210/jc.2012-3943 pmid:23553862

    CrossRefPubMed
12. 12.↵
    1. Feng M,
    2. Liu Z,
    3. Liu X, et al

    . Diagnosis and outcomes of 341 patients with Cushing’s disease following transsphenoid surgery: a single-center experience. World Neurosurg 2018;109:e75–80 doi:10.1016/j.wneu.2017.09.105 pmid:28951275

    CrossRefPubMed
13. 13.↵
    1. Rhoton AL

    . The sellar region. Neurosurgery 2002;51:S335–74 pmid:12234453

    CrossRefPubMed
14. 14.↵
    1. Castle-Kirszbaum M,
    2. Uren B,
    3. Goldschlager T

    . Anatomical variation for the endoscopic endonasal transsphenoidal approach. World Neurosurg 2021;156:111–19 doi:10.1016/j.wneu.2021.09.103] pmid:34610448

    CrossRefPubMed
15. 15.↵
    1. Parkinson D

    . Extradural neural axis compartment. J Neurosurg 2000;92:585–88 doi:10.3171/jns.2000.92.4.0585 pmid:10761646

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Bonneville JF,
    2. Bonneville F,
    3. Cattin F, et al

    . MRI of the Pituitary Gland. Springer-Verlag International Publishing; 2016
17. 17.↵
    1. Castle-Kirszbaum M,
    2. Maingard J,
    3. Lim RP, et al

    . Four-dimensional magnetic resonance imaging assessment of intracranial aneurysms: a state-of-the-art review. Neurosurgery 2020;87:453–65 doi:10.1093/neuros/nyaa021 pmid:34415482

    CrossRefPubMed
18. 18.↵
    1. Manavela MP,
    2. Goodall CM,
    3. Katz SB, et al

    . The association of Cushing’s disease and primary empty sella turcica. Pituitary 2001;4:145–51 doi:10.1023/a:1015310806063 pmid:12138987

    CrossRefPubMed
19. 19.↵
    1. Himes BT,
    2. Bhargav AG,
    3. Brown DA, et al

    . Does pituitary compression/empty sella syndrome contribute to MRI-negative Cushing’s disease? A single-institution experience. Neurosurg Focus 2020;48:E3 doi:10.3171/2020.3.FOCUS2084 pmid:32480375

    CrossRefPubMed
20. 20.↵
    1. Miki Y,
    2. Matsuo M,
    3. Nishizawa S, et al

    . Pituitary adenomas and normal pituitary tissue: enhancement patterns on gadopentetate-enhanced MR imaging. Radiology 1990;177:35–38 doi:10.1148/radiology.177.1.2399335 pmid:2399335

    CrossRefPubMed
21. 21.↵
    1. Viacava P,
    2. Gasperi M,
    3. Acerbi G, et al

    . Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 2003;26:23–28 doi:10.1007/BF03345118 pmid:12602530

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Perez-Millan MI,
    2. Berner SI,
    3. Luque GM, et al

    . Enhanced nestin expression and small blood vessels in human pituitary adenomas. Pituitary 2013;16:303–10 doi:10.1007/s11102-012-0421-9 pmid:22886682

    CrossRefPubMed
23. 23.↵
    1. Chatain GP,
    2. Patronas N,
    3. Smirniotopoulos JG, et al

    . Potential utility of FLAIR in MRI-negative Cushing’s disease. J Neurosurg 2018;129:620–28 doi:10.3171/2017.4.JNS17234 pmid:29027863

    CrossRefPubMed
24. 24.↵
    1. Pui MH,
    2. Fok EC

    . MR imaging of the brain: comparison of gradient-echo and spin-echo pulse sequences. AJR Am J Roentgenol 1995;165:959–62 doi:10.2214/ajr.165.4.7677001 pmid:7677001

    CrossRefPubMed
25. 25.↵
    1. Wang J,
    2. Wu Y,
    3. Yao Z, et al

    . Assessment of pituitary micro-lesions using 3D sampling perfection with application-optimized contrasts using different flip-angle evolutions. Neuroradiology 2014;56:1047–53 doi:10.1007/s00234-014-1432-1 pmid:25249174

    CrossRefPubMed
26. 26.↵
    1. Baumert B,
    2. Wörtler K,
    3. Steffinger D, et al

    . Assessment of the internal craniocervical ligaments with a new magnetic resonance imaging sequence: three-dimensional turbo spin echo with variable flip-angle distribution (SPACE). Magn Reson Imaging 2009;27:954–60 doi:10.1016/j.mri.2009.01.012 pmid:19282121

    CrossRefPubMed
27. 27.↵
    1. Watanabe Y,
    2. Makidono A,
    3. Nakamura M, et al

    . 3D MR cisternography to identify distal dural rings: comparison of 3D-CISS and 3D-SPACE sequences. Magn Reson Med Sci 2011;10:29–32 doi:10.2463/mrms.10.29 pmid:21441725

    CrossRefPubMed
28. 28.↵
    1. Moher D,
    2. Liberati A,
    3. Tetzlaff J, et al

    ; for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535–53 doi:10.1136/bmj.b2535 pmid:19622551

    FREE Full Text
29. 29.↵
    1. Slim K,
    2. Nini E,
    3. Forestier D, et al

    . Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 2003;73:712–16 doi:10.1046/j.1445-2197.2003.02748.x pmid:12956787

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Erickson D,
    2. Erickson B,
    3. Watson R, et al

    . 3 Tesla magnetic resonance imaging with and without corticotropin releasing hormone stimulation for the detection of microadenomas in Cushing’s syndrome. Clin Endocrinol (Oxf) 2010;72:793–99 doi:10.1111/j.1365-2265.2009.03723.x pmid:19811509

    CrossRefPubMed
31. 31.↵
    1. Kim LJ,
    2. Lekovic GP,
    3. White WL, et al

    . Preliminary experience with 3-Tesla MRI and Cushing’s disease. Skull Base 2007;17:273–77 doi:10.1055/s-2007-985196 pmid:18174929

    CrossRefPubMed
32. 32.↵
    1. Stobo DB,
    2. Lindsay RS,
    3. Connell JM, et al

    . Initial experience of 3 Tesla versus conventional field strength magnetic resonance imaging of small functioning pituitary tumours. Clin Endocrinol (Oxf) 2011;75:673–77 doi:10.1111/j.1365-2265.2011.04098.x pmid:21609346

    CrossRefPubMed
33. 33.↵
    1. de Rotte AA,
    2. Groenewegen A,
    3. Rutgers DR, et al

    . High-resolution pituitary gland MRI at 7.0 Tesla: a clinical evaluation in Cushing’s disease. Eur Radiol 2016;26:271–77 doi:10.1007/s00330-015-3809-x pmid:25991481

    CrossRefPubMed
34. 34.↵
    1. Wu Y,
    2. Cai Y,
    3. Rui W, et al

    . Contrast-enhanced 3D-T2-weighted SPACE sequence for MRI detection and localization of adrenocorticotropin (ACTH)-secreting pituitary microadenomas. Clin Endocrinol (Oxf) 2022;96:578–88 doi:10.1111/cen.14574 pmid:34323314

    CrossRefPubMed
35. 35.↵
    1. Zhang K,
    2. Shen M,
    3. Qiao N, et al

    . Surgical outcomes and multidisciplinary management strategy of Cushing’s disease: a single-center experience in China. Neurosurg Focus 2020;48:E7 doi:10.3171/2020.3.FOCUS2067 pmid:32480378

    CrossRefPubMed
36. 36.↵
    1. Lang M,
    2. Habboub G,
    3. Moon D, et al

    . Comparison of constructive interference in steady-state and T1-weighted MRI sequence at detecting pituitary adenomas in Cushing’s disease patients. J Neurol Surg B Skull Base 2018;79:593–98 doi:10.1055/s-0038-1642032 pmid:30456030

    CrossRefPubMed
37. 37.↵
    1. Tabarin A,
    2. Laurent F,
    3. Catargi B, et al

    . Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing’s disease. Clin Endocrinol (Oxf) 1998;49:293–300 doi:10.1046/j.1365-2265.1998.00541.x pmid:9861318

    CrossRefPubMed
38. 38.↵
    1. Grober Y,
    2. Grober H,
    3. Wintermark M, et al

    . Comparison of MRI techniques for detecting microadenomas in Cushing’s disease. J Neurosurg 2018;128:1051–57 doi:10.3171/2017.3.JNS163122 pmid:28452619

    CrossRefPubMed
39. 39.↵
    1. Yogi-Morren D,
    2. Habra MA,
    3. Faiman C, et al

    . Pituitary MRI findings in patients with pituitary and ectopic ACTH-dependent Cushing syndrome: does a 6-mm pituitary tumor size cut-off value exclude ectopic ACTH syndrome? Endocr Pract 2015;21:1098–103 doi:10.4158/EP15662.OR pmid:26121435

    CrossRefPubMed
40. 40.↵
    1. Vitale G,
    2. Tortora F,
    3. Baldelli R

    ; A.B.C. Group, et al. Pituitary magnetic resonance imaging in Cushing’s disease. Endocrine 2017;55:691–99 doi:10.1007/s12020-016-1038-y pmid:27435590

    CrossRefPubMed
41. 41.↵
    1. Bashari WA,
    2. Gillett D,
    3. MacFarlane J, et al

    . Modern imaging in Cushing’s disease. Pituitary 2022;25:709–12 doi:10.1007/s11102-022-01236-w pmid:35666391

    CrossRefPubMed
42. 42.↵
    1. Portocarrero-Ortiz L,
    2. Bonifacio-Delgadillo D,
    3. Sotomayor-González A, et al

    . A modified protocol using half-dose gadolinium in dynamic 3-Tesla magnetic resonance imaging for detection of ACTH-secreting pituitary tumors. Pituitary 2010;13:230–35 doi:10.1007/s11102-010-0222-y pmid:20182808

    CrossRefPubMed
43. 43.↵
    1. Coburger J,
    2. König R,
    3. Seitz K, et al

    . Determining the utility of intraoperative magnetic resonance imaging for transsphenoidal surgery: a retrospective study: clinical article. J Neurosurg 2014;120:346–56 doi:10.3171/2013.9.JNS122207 pmid:24329023

    CrossRefPubMed
44. 44.↵
    1. Jones PS,
    2. Swearingen B

    . Intraoperative MRI for pituitary adenomas. Neurosurg Clin N Am 2019;30:413–20 doi:10.1016/j.nec.2019.05.003 pmid:31471048

    CrossRefPubMed
45. 45.↵
    1. Chittiboina P,
    2. Talagala SL,
    3. Merkle H, et al

    . Endosphenoidal coil for intraoperative magnetic resonance imaging of the pituitary gland during transsphenoidal surgery. J Neurosurg 2016;125:1451–59 doi:10.3171/2015.11.JNS151465 pmid:26991390

    CrossRefPubMed
46. 46.↵
    1. Lonser RR,
    2. Ksendzovsky A,
    3. Wind JJ, et al

    . Prospective evaluation of the characteristics and incidence of adenoma-associated dural invasion in Cushing disease. J Neurosurg 2012;116:272–79 doi:10.3171/2011.8.JNS11456 pmid:21923247

    CrossRefPubMed
47. 47.↵
    1. Cohen-Cohen S,
    2. Gardner PA,
    3. Alves-Belo JT, et al

    . The medial wall of the cavernous sinus, Part 2: selective medial wall resection in 50 pituitary adenoma patients. J Neurosurg 2018;131:131–40 doi:10.3171/2018.5.JNS18595 pmid:30192191

    CrossRefPubMed
48. 48.↵
    1. Berkmann S,
    2. Roethlisberger M,
    3. Mueller B, et al

    . Selective resection of Cushing microadenoma guided by preoperative hybrid 18-fluoroethyl-L-tyrosine and 11-C-methionine PET/MRI. Pituitary 2021;24:878–86 doi:10.1007/s11102-021-01160-5 pmid:34155554

    CrossRefPubMed
49. 49.↵
    1. Chittiboina P,
    2. Montgomery BK,
    3. Millo C, et al

    . High-resolution (18)F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease. J Neurosurg 2015;122:791–97 doi:10.3171/2014.10.JNS14911 pmid:25479121

    CrossRefPubMed
50. 50.↵
    1. Boyle J,
    2. Patronas NJ,
    3. Smirniotopoulos J, et al

    . CRH stimulation improves (18)F-FDG-PET detection of pituitary adenomas in Cushing’s disease. Endocrine 2019;65:155–65 doi:10.1007/s12020-019-01944-7 pmid:31062234

    CrossRefPubMed
51. 51.↵
    1. Walia R,
    2. Gupta R,
    3. Bhansali A, et al

    . Molecular imaging targeting corticotropin-releasing hormone receptor for corticotropinoma: a changing paradigm. J Clin Endocrinol Metab 2021;106:e1816–26 doi:10.1210/clinem/dgaa755 pmid:33079979

    CrossRefPubMed